Background
Background HypothalamicĤypothalamicp ituitary^adrenal (HPA) axis function, as pituitary^adrenal (HPA) axis function, as variously measured by the responses to variously measured by the responses to the combined dexamethasone/ the combined dexamethasone/ corticotrophin-releasing hormone corticotrophin-releasing hormone (dex/CRH) test, the dexamethasone (dex/CRH) test, the dexamethasone suppression test (DST) and basal cortisol suppression test (DST) and basal cortisol levels, has been reported to be abnormal levels, has been reported to be abnormal in bipolar disorder. in bipolar disorder.
Aims Aims To test the hypothesis that HPA
To test the hypothesis that HPA axis dysfunction persists in patients in axis dysfunction persists in patients in remission from bipolar disorder. remission from bipolar disorder.
Method
Method Salivary cortisollevels and the Salivary cortisollevels and the plasma cortisol response to the DSTand plasma cortisol response to the DSTand dex/CRH test were examined in 53 dex/CRH test were examined in 53 patients with bipolar disorder, 27 of whom patients with bipolar disorder, 27 of whom fulfilled stringent criteria for remission, fulfilled stringent criteria for remission, and in 28 healthy controls. Serum and in 28 healthy controls. Serum dexamethasone levels were measured. dexamethasone levels were measured.
Results

Results Patients with bipolar disorder
Patients with bipolar disorder demonstrated an enhanced cortisol demonstrated an enhanced cortisol response to the dex/CRH test compared response to the dex/CRH test compared with controls ( with controls (P P¼0.001).This response did 0.001).This response did not differ significantly between remitted not differ significantly between remitted and non-remitted patients.These findings and non-remitted patients.These findings were present after the potentially were present after the potentially confounding effects of dexamethasone confounding effects of dexamethasone levels were accounted for. levels were accounted for.
Conclusions Conclusions The dex/CRH test is
The dex/CRH test is abnormal in both remitted and non-abnormal in both remitted and nonremitted patients with bipolar disorder. remitted patients with bipolar disorder. This measure of HPA axis dysfunction is a This measure of HPA axis dysfunction is a potential trait marker in bipolar disorder potential trait marker in bipolar disorder and thus possibly indicative of the core and thus possibly indicative of the core pathophysiological process in this illness. pathophysiological process in this illness. Genes, childhood adversity and life events Genes, childhood adversity and life events in adulthood contribute to the development in adulthood contribute to the development of mood disorders, possibly via effects on of mood disorders, possibly via effects on hypothalamic-pituitary-adrenal (HPA) axis hypothalamic-pituitary-adrenal (HPA) axis function. This is supported by the finding function. This is supported by the finding that healthy probands with a family history that healthy probands with a family history of mood disorder show abnormalities on of mood disorder show abnormalities on the dexamethasone/corticotrophin-releasing the dexamethasone/corticotrophin-releasing hormone (dex/CRH) test (Holsboer hormone (dex/CRH) test (Holsboer et al et al, , 1995) . However, although the response to 1995). However, although the response to the dex/CRH test is abnormal in sympto-the dex/CRH test is abnormal in symptomatic patients with bipolar disorder it has matic patients with bipolar disorder it has not been shown consistently to normalise not been shown consistently to normalise with symptom resolution (Schmider with symptom resolution (Schmider et al et al, , 1995; Rybakowski & Twardowska, 1999 ), 1995 Rybakowski & Twardowska, 1999 ), suggesting that it may not simply be an epi-suggesting that it may not simply be an epiphenomenon of illness. To test this further, phenomenon of illness. To test this further, we examined HPA axis function in 53 we examined HPA axis function in 53 patients with bipolar disorder, including patients with bipolar disorder, including 27 who fulfilled stringent prospective 27 who fulfilled stringent prospective criteria for remission, and in a further criteria for remission, and in a further 28 healthy comparison participants. We 28 healthy comparison participants. We hypothesised that if HPA axis dysfunction hypothesised that if HPA axis dysfunction is a trait abnormality, it would be present is a trait abnormality, it would be present in both remitted and non-remitted patients. in both remitted and non-remitted patients.
Declaration of interest
METHOD METHOD
Study participants Study participants
Fifty-three patients (age range 23-62 years) Fifty-three patients (age range 23-62 years) with bipolar disorder were recruited from with bipolar disorder were recruited from out-patient clinics in secondary and tertiary out-patient clinics in secondary and tertiary care in the north-east of England. Diag-care in the north-east of England. Diagnosis, illness characteristics, clinical ratings nosis, illness characteristics, clinical ratings and medication history were determined by and medication history were determined by trained psychiatrists using the Structured trained psychiatrists using the Structured Clinical Interview for DSM-IV (SCID; First Clinical Interview for DSM-IV (SCID; First et al et al, 1997) , case note and medication , 1997), case note and medication review and standardised rating scales. review and standardised rating scales.
Patients in remission were rated pro-Patients in remission were rated prospectively over 4 weeks and defined as re-spectively over 4 weeks and defined as remitted if they satisfied the criteria of the mitted if they satisfied the criteria of the Newcastle Euthymia Protocol (Thompson Newcastle Euthymia Protocol (Thompson et al et al, 2000) . Briefly, these criteria consist , 2000). Briefly, these criteria consist of a SCID diagnosis of bipolar disorder in of a SCID diagnosis of bipolar disorder in full remission, with a 21-item Hamilton full remission, with a 21-item Hamilton Rating Scale for Depression (HRSD; Rating Scale for Depression (HRSD; 1997) , completed at , 1997), completed at weekly intervals throughout the assessment weekly intervals throughout the assessment period are required to remain unchanged period are required to remain unchanged from baseline. The time spent in clinically from baseline. The time spent in clinically defined remission was also determined. defined remission was also determined. The non-remitted patients who satisfied The non-remitted patients who satisfied the SCID diagnostic criteria for bipolar the SCID diagnostic criteria for bipolar disorder current episode depressive were disorder current episode depressive were classified as depressed. classified as depressed.
Twenty-eight control participants (age Twenty-eight control participants (age range 24-60 years) were recruited. They range 24-60 years) were recruited. They were confirmed as healthy by medical ex-were confirmed as healthy by medical examination and by the SCID to be free of amination and by the SCID to be free of neurological or psychiatric disorder. No neurological or psychiatric disorder. No control participant gave a history of hav-control participant gave a history of having a first-ing a first-degree relative with psychiatric degree relative with psychiatric disorder. Both patients and controls were disorder. Both patients and controls were excluded if they had a neurological or med-excluded if they had a neurological or medical condition, if they were taking cortico-ical condition, if they were taking corticosteroids or antihypertensive medication or steroids or antihypertensive medication or had a history of substance or alcohol mis-had a history of substance or alcohol misuse. Gender, age and menstrual status have use. Gender, age and menstrual status have been reported previously to have an impact been reported previously to have an impact on HPA axis function (Viau & Meaney, on HPA axis function (Viau & Meaney, 1991; Seeman 1991; Seeman et al et al, 2001 .36) 0.36) and the impact of these variables on the and the impact of these variables on the neuroendocrine output was determined. neuroendocrine output was determined. The Joint Newcastle and North Tyneside The Joint Newcastle and North Tyneside Ethics Committee approved the study. All Ethics Committee approved the study. All participants gave written informed consent. participants gave written informed consent.
Neuroendocrine testing Neuroendocrine testing
The dex/CRH test was performed follow-The dex/CRH test was performed following the protocol previously used in studies ing the protocol previously used in studies of major depressive disorder (Heuser of major depressive disorder (Heuser et al et al, , 1994) . Participants took 1.5 mg dexa-1994). Participants took 1.5 mg dexamethasone orally at 23.00 h on the evening methasone orally at 23.00 h on the evening before neuroendocrine testing. They at-before neuroendocrine testing. They attended the research unit on the morning tended the research unit on the morning of the test day and had a light lunch at of the test day and had a light lunch at noon, following which they were canu-noon, following which they were canulated in the antecubital fossa at 13.00 h. lated in the antecubital fossa at 13.00 h. Participants then fasted, remained semi-Participants then fasted, remained semisupine and did not sleep. Human CRH supine and did not sleep. Human CRH (Ufelfingen, Switzerland) 100 (Ufelfingen, Switzerland) 100 m mg was ad-g was administered over 30 s via the canula at ministered over 30 s via the canula at 15.00 h. Blood was taken serially for mea-15.00 h. Blood was taken serially for measurement of cortisol levels at surement of cortisol levels at 15-minute 15-minute intervals until 17.00 h. The dexamethasone intervals until 17.00 h. The dexamethasone suppression test (DST) response was deter-suppression test (DST) response was determined by the 15.00 h (pre-CRH) mined by the 15.00 h (pre-CRH) cortisol cortisol level. Participants lightly chewed a citric-level. Participants lightly chewed a citricacid-impregnated acid-impregnated cotton-wool salivette cotton-wool salivette (Sarstedt, UK) at 08.00, 12.00, 16.00 and (Sarstedt, UK) at 08.00, 12.00, 16.00 and 20.00 h on the day prior to neuroendocrine 20.00 h on the day prior to neuroendocrine testing to allow assessment of both basal testing to allow assessment of both basal cortisol secretion and diurnal variation cortisol secretion and diurnal variation (Kirschbaum & Hellhammer, 1994) . Parti-(Kirschbaum & Hellhammer, 1994) . Participants were permitted to smoke as usual cipants were permitted to smoke as usual throughout the procedure to reduce any throughout the procedure to reduce any effects of nicotine withdrawal. effects of nicotine withdrawal.
Biochemical measures Biochemical measures
Blood was collected in ethylenediamine-Blood was collected in ethylenediaminetetracetic acid and centrifuged at 1000 tetracetic acid and centrifuged at 1000 g g for for 10 min to prepare plasma, which was re-10 min to prepare plasma, which was removed and immediately frozen at moved and immediately frozen at 7 720 20 8 8C C until assayed. Dexamethasone was assayed until assayed. Dexamethasone was assayed at Emory University, Georgia, using a at Emory University, Georgia, using a method described previously (Ritchie method described previously (Ritchie et al et al, , 1990) . In this laboratory, the 80%, 50% 1990). In this laboratory, the 80%, 50% and 20% binding points averaged to 0.07, and 20% binding points averaged to 0.07, 0.33 and 1.46 ng/ml, respectively. At a level 0.33 and 1.46 ng/ml, respectively. At a level of 0.52 ng/ml, the inter-assay coefficient of of 0.52 ng/ml, the inter-assay coefficient of variation was 8% and the intra-assay variation was 8% and the intra-assay coefficient of variation was 4%. Cortisol coefficient of variation was 4%. Cortisol was determined using corti-cote radio-was determined using corti-cote radioimmunoassay kits (ICN Pharmaceuticals, immunoassay kits (ICN Pharmaceuticals, California, USA). The sensitivity of the California, USA). The sensitivity of the plasma cortisol assay was 1.9 nmol/l. plasma cortisol assay was 1.9 nmol/l. The The inter-assay and intra-assay coef inter-assay and intra-assay coefficients of ficients of variation for the low (107.7 nmol/l), med-variation for the low (107.7 nmol/l), medium (25.1 nmol/l) and high (51.1 nmol/l) ium (25.1 nmol/l) and high (51.1 nmol/l) quality controls were 5.9%, 7.8%, 9.6% quality controls were 5.9%, 7.8%, 9.6% and 7.7%, 6.6%, 9.4%, respectively. and 7.7%, 6.6%, 9.4%, respectively.
Saliva collected using the salivette sys-Saliva collected using the salivette system was extracted from the cotton-wool tem was extracted from the cotton-wool swab by centrifugation and stored at swab by centrifugation and stored at 7 720 20 8 8C until analysis. Samples were ana-C until analysis. Samples were analysed for cortisol using radioimmunoassay. lysed for cortisol using radioimmunoassay. The sensitivity of the saliva cortisol assay The sensitivity of the saliva cortisol assay was 0.08 nmol/l at 98% binding and the was 0.08 nmol/l at 98% binding and the inter-assay and intra-assay coefficients of inter-assay and intra-assay coefficients of variation for the low (8.6 nmol/l), medium variation for the low (8.6 nmol/l), medium (31.5 nmol/l) and high (87.5 nmol/l) quality (31.5 nmol/l) and high (87.5 nmol/l) quality controls were 17.2%, 10.3%, 9.6% and controls were 17.2%, 10.3%, 9.6% and 25.8%, 16.3%, 9.1%, respectively. 25.8%, 16.3%, 9.1%, respectively.
Effect of treatments Effect of treatments
Dexamethasone clearance is increased in Dexamethasone clearance is increased in patients receiving drugs, including carba-patients receiving drugs, including carbamazepine, which induces the main enzyme mazepine, which induces the main enzyme involved in dexamethasone clearance, involved in dexamethasone clearance, CYP3A4, potentially producing false-CYP3A4, potentially producing falsepositive DST results. Medication may also positive DST results. Medication may also exert effects on cortisol output that are in-exert effects on cortisol output that are independent of dexamethasone metabolism. dependent of dexamethasone metabolism.
We therefore also examined the effect We therefore also examined the effect of carbamazepine levels and other medi-of carbamazepine levels and other medications on dexamethasone and cortisol cations on dexamethasone and cortisol output. output.
Statistical analysis Statistical analysis
For statistical analysis we used SPSS for For statistical analysis we used SPSS for Windows, version 9. Data were first ex-Windows, version 9. Data were first examined to see whether they fulfilled the amined to see whether they fulfilled the assumptions for parametric statistical ana-assumptions for parametric statistical analyses. If violations of these assumptions lyses. If violations of these assumptions occurred, data were logarithmically trans-occurred, data were logarithmically transformed (to base ten). If this failed to satisfy formed (to base ten). If this failed to satisfy assumptions, the data were analysed non-assumptions, the data were analysed nonparametrically. Basal cortisol was logarith-parametrically. Basal cortisol was logarithmically transformed to normalise the mically transformed to normalise the distribution and compared between groups distribution and compared between groups using repeated-measures ANOVA, with the using repeated-measures ANOVA, with the four time points as the within-subject vari-four time points as the within-subject variable. The mean and 95% confidence inter-able. The mean and 95% confidence interval (CI) of mean basal cortisol levels were val (CI) of mean basal cortisol levels were calculated. All other data were analysed calculated. All other data were analysed non-parametrically. Kruskal-Wallis one-non-parametrically. Kruskal-Wallis oneway ANOVA on ranks was utilised to de-way ANOVA on ranks was utilised to determine group differences when comparing termine group differences when comparing more than two groups. Non-parametric more than two groups. Non-parametric data are reported as median and 95% CI data are reported as median and 95% CI of the median. When comparing two of the median. When comparing two groups, the median difference (Campbell groups, the median difference (Campbell & & Gardner, 2000) and Mann-Whitney Gardner, 2000) and Mann-Whitney U U-test were used.
-test were used. Correlations were carried out using Correlations were carried out using Spearman's rank coefficient ( Spearman's rank coefficient (r r s s ). Categori-). Categorical variables were analysed using cal variables were analysed using w w 2 2 tests. tests. The 15.00 h (immediately pre-CRH) plas-The 15.00 h (immediately pre-CRH) plasma cortisol was used for analysis of the ma cortisol was used for analysis of the DST. Delta cortisol (the difference between DST. Delta cortisol (the difference between the peak cortisol response to the dex/CRH the peak cortisol response to the dex/CRH test and the 15.00 h cortisol plasma concen-test and the 15.00 h cortisol plasma concentration) was used for analysis of the dex/ tration) was used for analysis of the dex/ CRH response. To investigate whether the CRH response. To investigate whether the results differ between patients and controls, results differ between patients and controls, receiver operating characteristic curves receiver operating characteristic curves were plotted for basal cortisol area under were plotted for basal cortisol area under the curve, 15.00 h plasma cortisol and delta the curve, 15.00 h plasma cortisol and delta cortisol. The area under the receiver operat-cortisol. The area under the receiver operating characteristic curve and the 95% CI ing characteristic curve and the 95% CI were determined using the Wilcoxon esti-were determined using the Wilcoxon estimate. All cortisol levels are presented as mate. All cortisol levels are presented as nmol/l and plasma dexamethasone levels nmol/l and plasma dexamethasone levels as pmol/l. Based on the effect size seen in as pmol/l. Based on the effect size seen in the most recent study comparing patients the most recent study comparing patients with symptomatic and asymptomatic bi-with symptomatic and asymptomatic bipolar disorder (Schmider polar disorder (Schmider et al et al, 1995) , the , 1995), the principal comparisons of remitted with principal comparisons of remitted with non-remitted patients and remitted with non-remitted patients and remitted with depressed patients had a power of depressed patients had a power of 4 499% 99% at the 0.05 level of significance. Because at the 0.05 level of significance. Because carbamazepine had such a profound effect carbamazepine had such a profound effect on dexamethasone metabolism, on dexamethasone metabolism, post hoc post hoc analysis was performed after exclusion of analysis was performed after exclusion of patients taking carbamazepine. patients taking carbamazepine.
Dexamethasone levels Dexamethasone levels
Earlier studies have demonstrated that Earlier studies have demonstrated that there is marked variability in serum dexa-there is marked variability in serum dexamethasone levels during the DST and that methasone levels during the DST and that the rate of dexamethasone metabolism the rate of dexamethasone metabolism and hence dexamethasone levels are a and hence dexamethasone levels are a significant determinant of DST response significant determinant of DST response (Morris (Morris et al et al, 1986; Lowy & Meltzer, , 1986; Lowy & Meltzer, 1987; Stokes 1987; Stokes et al et al, 2002 Stokes et al et al, , 2002a . There is a mid-). There is a middle range of dexamethasone values below dle range of dexamethasone values below which individuals tend to escape from which individuals tend to escape from DST suppression and above which they DST suppression and above which they tend to suppress (Ritchie tend to suppress (Ritchie et al et al, 1990) . It , 1990 ). It has been suggested, therefore, that the has been suggested, therefore, that the DST may not be valid in people whose DST may not be valid in people whose dexamethasone levels fall outside this win-dexamethasone levels fall outside this window and these individuals should be ex-dow and these individuals should be excluded from analysis (Morris cluded from analysis (Morris et al et al, 1986; , 1986; Lowy & Meltzer, 1987; Stokes Lowy & Meltzer, 1987; Stokes et al et al, , 2002 2002a a). However, it has been argued that ). However, it has been argued that enhanced metabolism of dexamethasone is enhanced metabolism of dexamethasone is a component of affective illness and may a component of affective illness and may be secondary to hepatic enzyme induction be secondary to hepatic enzyme induction in hypercortisolaemic subjects (Holsboer in hypercortisolaemic subjects (Holsboer et al et al, 1986; Stokes , 1986; Stokes et al et al, 2002 Stokes et al et al, , 2002b . ). Cut-off points for the dexamethasone Cut-off points for the dexamethasone window analysis were defined empirically window analysis were defined empirically according to the method of Ritchie according to the method of Ritchie et al et al, , 1990 ) as 0.85 and 2.5 pmol/l. 1990) as 0.85 and 2.5 pmol/l.
RESULTS
Illness characteristics Illness characteristics
A total of 53 patients with bipolar disorder A total of 53 patients with bipolar disorder participated in the study, of whom 27 were participated in the study, of whom 27 were remitted as defined above (Thompson remitted as defined above (Thompson et al et al, , 2000) ; 26 were non-remitted, 14 of whom 2000); 26 were non-remitted, 14 of whom met the full criteria for depression and the met the full criteria for depression and the other 12 had sub-threshold symptoms other 12 had sub-threshold symptoms (Table 1) . Of the remitted patients, 5 were (Table 1) . Of the remitted patients, 5 were on antidepressants (1 on mirtazepine, 3 on on antidepressants (1 on mirtazepine, 3 on a selective serotonin reuptake inhibitor a selective serotonin reuptake inhibitor and 1 on trazodone), 4 were on typical anti-and 1 on trazodone), 4 were on typical antipsychotics and 2 on atypical antipsychotics, psychotics and 2 on atypical antipsychotics, 17 were on lithium, 2 on lamotrigine, 5 on 17 were on lithium, 2 on lamotrigine, 5 on carbamazepine, 2 on gabapentin and 2 on carbamazepine, 2 on gabapentin and 2 on benzodiazepines. Of the non-remitted pa-benzodiazepines. Of the non-remitted patients, 10 were on at least one antidepres-tients, 10 were on at least one antidepressant (2 on mirtazepine, 2 on trazodone, 5 sant (2 on mirtazepine, 2 on trazodone, 5 on a selective serotonin reuptake inhibitor, on a selective serotonin reuptake inhibitor, 1 on reboxetine and 3 on venlafaxine), 7 1 on reboxetine and 3 on venlafaxine), 7 were taking typical and 7 atypical anti-were taking typical and 7 atypical antipsychotics, 9 were on lithium, 11 on psychotics, 9 were on lithium, 11 on valproate, 9 on carbamazepine, 3 on gaba-valproate, 9 on carbamazepine, 3 on gabapentin and 6 on lamotrigine. No patient or pentin and 6 on lamotrigine. No patient or control participant was on the oral control participant was on the oral contraceptive pill. contraceptive pill.
Responses for patients with bipolar Responses for patients with bipolar disorder compared with controls disorder compared with controls
The DST The DST
The 15.00 h plasma cortisol levels were sig-The 15.00 h plasma cortisol levels were significantly higher in patients with bipolar nificantly higher in patients with bipolar disorder than in controls ( disorder than in controls (P P¼0.017). Simi-0.017). Similarly, the area under the receiver operating larly, the area under the receiver operating characteristic curve revealed that patients characteristic curve revealed that patients with bipolar disorder could be discrimi-with bipolar disorder could be discriminated from controls using the 15.00 h corti-nated from controls using the 15.00 h cortisol level. The difference in 15.00 h cortisol sol level. The difference in 15.00 h cortisol concentrations between remitted and non-concentrations between remitted and nonremitted patients and controls was present remitted patients and controls was present at the trend level ( at the trend level (P P¼0.058) (see Table 2 ). 0.058) (see Table 2 ).
Cortisol response to the dex/CRH test Cortisol response to the dex/CRH test
Dexamethasone and human CRH were Dexamethasone and human CRH were well tolerated by all subjects and, other well tolerated by all subjects and, other than transient facial flushing, no side-than transient facial flushing, no sideeffects effects were experienced. Delta cortisol were experienced. Delta cortisol was significantly greater in patients with bi-was significantly greater in patients with bipolar disorder than in controls ( polar disorder than in controls (P P¼0.001). 0.001).
The area under the receiver operating char-The area under the receiver operating characteristic curve revealed that patients with acteristic curve revealed that patients with bipolar disorder could be discriminated bipolar disorder could be discriminated from controls using delta cortisol. Examin-from controls using delta cortisol. Examination of cortisol response to dex/CRH chal-ation of cortisol response to dex/CRH challenge in remitted and non-remitted patients lenge in remitted and non-remitted patients and controls revealed a significant group and controls revealed a significant group difference. difference. Post hoc Post hoc analysis revealed that analysis revealed that delta cortisol was significantly greater in re-delta cortisol was significantly greater in remitted ( mitted (P P¼0.004), non-remitted ( 0.004), non-remitted (P P¼0.003) 0.003) and depressed patients ( and depressed patients (P P¼0.02) than in 0.02) than in controls. There was no significant differ-controls. There was no significant difference in delta cortisol levels between ence in delta cortisol levels between depressed patients and controls, between depressed patients and controls, between remitted and non-remitted patients or remitted and non-remitted patients or between remitted and depressed patients between remitted and depressed patients ( Table 2 and Fig. 1 ).
( Table 2 and Fig. 1 ).
Correlations and predictions Correlations and predictions
The cortisol response to the dex/CRH The cortisol response to the dex/CRH test did not differ between males and test did not differ between males and females or between pre-menopausal and females or between pre-menopausal and post-menopausal post-menopausal females. Neither age nor females. Neither age nor cycle frequency correlated with delta cycle frequency correlated with delta 4 9 8 4 9 8 The area under the receiver operating characteristic curve revealed that patients with acteristic curve revealed that patients with bipolar disorder could not be discriminated bipolar disorder could not be discriminated reliably from controls using this measure. reliably from controls using this measure. Basal salivary cortisol levels between Basal salivary cortisol levels between remitted and non-remitted patients and con-remitted and non-remitted patients and controls did not differ over time ( trols did not differ over time (F F[3,171] [3,171]¼3.5; 3.5; P P¼0.06) and there was no main effect 0.06) and there was no main effect of diagnosis and no time of diagnosis and no time6 6diagnosis diagnosis interaction ( interaction (P P4 40.3) (Table 3) . 0.3) (Table 3) .
Results from analysis after
Results from analysis after exclusion of patients with exclusion of patients with dexamethasone levels outside the dexamethasone levels outside the dexamethasone window dexamethasone window (see Fig. 2 ) (see Fig. 2 
)
Results are reported in Table 3 . The dexa-Results are reported in Table 3 . The dexamethasone window analysis included 21 methasone window analysis included 21 controls and 27 patients with bipolar disor-controls and 27 patients with bipolar disorder, of whom 14 were remitted. The results der, of whom 14 were remitted. The results remain unchanged except that delta cortisol remain unchanged except that delta cortisol was no longer significantly greater in was no longer significantly greater in depressed patients than in controls, depressed patients than in controls, 15.00 h cortisol levels (the DST response) 15.00 h cortisol levels (the DST response) were no longer greater in patients with were no longer greater in patients with bipolar disorder than in controls and the bipolar disorder than in controls and the 4 9 9 4 9 9
Fig. 1 Fig. 1 The median cortisol response to the dexamethasone/corticotrophin-releasing hormone test in The median cortisol response to the dexamethasone/corticotrophin-releasing hormone test in remitted and non-remitted patients and controls. remitted and non-remitted patients and controls. area under the receiver operating character-area under the receiver operating characteristic curve revealed that patients with bi-istic curve revealed that patients with bipolar disorder could not be differentiated polar disorder could not be differentiated reliably from controls using the DST reliably from controls using the DST response. response.
Effects of medication Effects of medication on dexamethasone levels on dexamethasone levels and cortisol response and cortisol response
Overall, patients taking carbamazepine Overall, patients taking carbamazepine had lower dexamethasone levels ( had lower dexamethasone levels (U U¼0.0; 0.0; P P5 50.0005), a higher delta cortisol level 0.0005), a higher delta cortisol level ( (U U¼56.0; 56.0; P P5 50.0005) and were more 0.0005) and were more likely to respond to the dex/CRH test likely to respond to the dex/CRH test than those not taking carbamazepine than those not taking carbamazepine (difference (difference¼63.4%, 63.4%, Fisher's exact test
Fisher's exact test P P5 50.0005). Overall, there were ten pa-0.0005). Overall, there were ten patients taking known CYP3A4-inhibiting tients taking known CYP3A4-inhibiting drugs. Dexamethasone levels or delta cor-drugs. Dexamethasone levels or delta cortisol did not differ between those taking tisol did not differ between those taking and not taking CYP3A4-inhibiting drugs, and not taking CYP3A4-inhibiting drugs, lithium or selective serotonin reuptake lithium or selective serotonin reuptake inhibitors (data not shown). inhibitors (data not shown).
DISCUSSION DISCUSSION
These data show that the cortisol response These data show that the cortisol response to the dex/CRH test is abnormal in patients to the dex/CRH test is abnormal in patients with bipolar disorder. Furthermore, re-with bipolar disorder. Furthermore, remitted patients continue to have an abnor-mitted patients continue to have an abnormal cortisol response to the dex/CRH test mal cortisol response to the dex/CRH test that cannot be differentiated from the that cannot be differentiated from the response of non-remitted patients (includ-response of non-remitted patients (including those who satisfy the SCID criteria for ing those who satisfy the SCID criteria for a depressive episode). These results were a depressive episode). These results were also evident after correcting for dexametha-also evident after correcting for dexamethasone levels. Basal cortisol does not differ sone levels. Basal cortisol does not differ between patients with bipolar disorder between patients with bipolar disorder and controls. and controls.
Confounding factors Confounding factors
Medication may have an impact on the cor-Medication may have an impact on the cortisol response. A number of studies have tisol response. A number of studies have shown that successful resolution of depres-shown that successful resolution of depressive symptoms normalises the HPA axis sive symptoms normalises the HPA axis (Heuser (Heuser et al et al, 1996; Nickel , 1996; Nickel et al et al, 2003) , 2003) but a recent study has shown that in the but a recent study has shown that in the absence of a treatment response antidepres-absence of a treatment response antidepressants did not alter the cortisol output on the sants did not alter the cortisol output on the dex/CRH test (Kunzel dex/CRH test (Kunzel et al et al, 2003) . Bschor , 2003) . Bschor et al et al (2002) have shown that lithium aug- (2002) have shown that lithium augmentation in treatment-resistant unipolar mentation in treatment-resistant unipolar depression increases the cortisol response depression increases the cortisol response to the dex/CRH test. However, in our study to the dex/CRH test. However, in our study patients on lithium did not have a greater patients on lithium did not have a greater cortisol response. All patients in this study cortisol response. All patients in this study taking carbamazepine had dexamethasone taking carbamazepine had dexamethasone levels outside the normal window and all levels outside the normal window and all had an abnormal response on the dex/ had an abnormal response on the dex/ CRH test. We found no other relationship CRH test. We found no other relationship between psychotropic medication and between psychotropic medication and dexamethasone levels. When dexametha-dexamethasone levels. When dexamethasone windows were applied, there was no sone windows were applied, there was no difference in dexamethasone levels between difference in dexamethasone levels between patients and controls, therefore an effect of patients and controls, therefore an effect of psychotropic medication on cortisol output psychotropic medication on cortisol output via dexamethasone metabolism appears via dexamethasone metabolism appears unlikely. unlikely.
After applying dexamethasone win-After applying dexamethasone windows, 33 of the 81 participants were ex-dows, 33 of the 81 participants were excluded but the study was still adequately cluded but the study was still adequately powered and the principal findings re-powered and the principal findings remained unchanged. Specifically, the dex/ mained unchanged. Specifically, the dex/ CRH test remained abnormal in patients CRH test remained abnormal in patients with bipolar disorder. Furthermore, re-with bipolar disorder. Furthermore, remitted patients continued to have an abnor-mitted patients continued to have an abnormal response to the dex/CRH test that mal response to the dex/CRH test that could not be could not be differentiated from the re-differentiated from the response of non-remitted sponse of non-remitted patients (including patients (including those who satisfy the SCID criteria for a de-those who satisfy the SCID criteria for a depressive episode). The reduced power after pressive episode). The reduced power after application of dexamethasone windows application of dexamethasone windows may explain the finding that the DST no may explain the finding that the DST no longer separated patients from controls. longer separated patients from controls.
The magnitude of the cortisol response The magnitude of the cortisol response to the dex/CRH test could not be predicted to the dex/CRH test could not be predicted by any single illness or demographic factor, by any single illness or demographic factor, including the period of remission in re-including the period of remission in remitted patients or the cycle frequency. This mitted patients or the cycle frequency. This suggests that the HPA axis dysfunction in suggests that the HPA axis dysfunction in patients with bipolar disorder does not patients with bipolar disorder does not have a temporal relationship to the period have a temporal relationship to the period of remission. of remission.
Measures of HPA axis function Measures of HPA axis function
We did not demonstrate elevation in basal We did not demonstrate elevation in basal salivary cortisol levels in patients with salivary cortisol levels in patients with bipolar disorder, whereas previous studies bipolar disorder, whereas previous studies employing serial plasma sampling techni-employing serial plasma sampling techniques at more frequent intervals have found ques at more frequent intervals have found clear evidence of hypercortisolaemia in clear evidence of hypercortisolaemia in bipolar disorder (Cervantes bipolar disorder (Cervantes et al et al, 2001) . , 2001). The relatively infrequent salivary sampling The relatively infrequent salivary sampling employed in this study may have failed to employed in this study may have failed to detect the subtleties of the pulsatile and detect the subtleties of the pulsatile and diurnal pattern of cortisol secretion diurnal pattern of cortisol secretion (Windle (Windle et al et al, 1998; Wong , 1998; Wong et al et al, 2000) , 2000) and hence did not uncover the hypercorti-and hence did not uncover the hypercortisolaemia that may be present in the patient solaemia that may be present in the patient group. Nevertheless, the DST and dex/CRH group. Nevertheless, the DST and dex/CRH tests are more sensitive than basal measures tests are more sensitive than basal measures of cortisol. There are a number of potential of cortisol. There are a number of potential explanations for this. It may be that the explanations for this. It may be that the extra complexity of the tests (addition of extra complexity of the tests (addition of dexamethasone and CRH) reveals addi-dexamethasone and CRH) reveals additional facets of the HPA axis (such as the tional facets of the HPA axis (such as the ability to respond to negative feedback ability to respond to negative feedback and positive drive; Holsboer & Barden, and positive drive; Holsboer & Barden, 1996) . Alternatively the dexamethasone 1996). Alternatively the dexamethasone and CRH challenge may exaggerate the dif-and CRH challenge may exaggerate the differences in HPA axis function between ferences in HPA axis function between patients with bipolar disorder and controls patients with bipolar disorder and controls or reduce the variance in response, thereby or reduce the variance in response, thereby allowing underlying differences in function allowing underlying differences in function to be revealed. to be revealed.
We did not measure the adrenocortico-We did not measure the adrenocorticotrophic hormone response to the dex/CRH trophic hormone response to the dex/CRH 5 0 0 5 0 0 test. Some previous studies have measured test. Some previous studies have measured adrenocorticotrophic hormone and cortisol adrenocorticotrophic hormone and cortisol but the adrenocorticotrophic hormone re-but the adrenocorticotrophic hormone responses tend to parallel cortisol responses sponses tend to parallel cortisol responses and therefore add little to the overall sen-and therefore add little to the overall sensitivity of the test (Heuser sitivity of the test (Heuser et al et al, 1994) . , 1994). Another potential criticism of our study is Another potential criticism of our study is that we did not examine patients in manic that we did not examine patients in manic or hypomanic states. Schmider or hypomanic states. Schmider et al et al (1995) have previously demonstrated that (1995) have previously demonstrated that the dex/CRH test is abnormal in patients the dex/CRH test is abnormal in patients with mania. Moreover, in addition to the with mania. Moreover, in addition to the practical problems, a recent prospective practical problems, a recent prospective study of patients with bipolar disorder re-study of patients with bipolar disorder reported that time spent in the depressive ported that time spent in the depressive spectrum predominates threefold over time spectrum predominates threefold over time with manic symptoms and fivefold over with manic symptoms and fivefold over time with cycling/mixed symptoms (Judd time with cycling/mixed symptoms (Judd et al et al, 2002) . The present study therefore , 2002) . The present study therefore examines patients with bipolar disorder in examines patients with bipolar disorder in the predominant clinical states. the predominant clinical states.
Comparison with previous research Comparison with previous research
Previous studies have shown that the HPA Previous studies have shown that the HPA axis is abnormal during a bipolar relapse axis is abnormal during a bipolar relapse and suggest some degree of normalisation and suggest some degree of normalisation but with residual abnormality on symptom but with residual abnormality on symptom resolution (Greden resolution (Greden et al et al, 1982; Schmider , 1982; Schmider et et al al, 1995; Rybakowski & Twardowska, , 1995; Rybakowski & Twardowska, 1999) . The present study is the first to use 1999). The present study is the first to use a rigorous prospective protocol to define a rigorous prospective protocol to define remission. The sample also had a mean remission. The sample also had a mean clinically defined duration of remission of clinically defined duration of remission of 2 years prior to entering the euthymic pro-2 years prior to entering the euthymic protocol. It is noteworthy that, in accordance tocol. It is noteworthy that, in accordance with previous studies, we found an abnor-with previous studies, we found an abnormal HPA axis during relapse. However, mal HPA axis during relapse. However, we also found that the response to the we also found that the response to the dex/CRH test remains abnormal to a dex/CRH test remains abnormal to a similar degree in remission. similar degree in remission.
In the Munich Vulnerability Study In the Munich Vulnerability Study (Holsboer (Holsboer et al et al, 1995) 54 apparently , 1995) 54 apparently healthy people with a family history of healthy people with a family history of affective disorder underwent a similar as-affective disorder underwent a similar assessment of HPA axis function. Only a min-sessment of HPA axis function. Only a minority of the subjects had a family history of ority of the subjects had a family history of bipolar rather than unipolar affective disor-bipolar rather than unipolar affective disorder. None the less, this demonstration of an der. None the less, this demonstration of an abnormal response to the dex/CRH test in a abnormal response to the dex/CRH test in a proportion of apparently healthy individ-proportion of apparently healthy individuals with a family history of affective dis-uals with a family history of affective disorder taken in conjunction with our data order taken in conjunction with our data suggests that HPA axis dysfunction may suggests that HPA axis dysfunction may be a trait abnormality in bipolar disorder. be a trait abnormality in bipolar disorder. Whether this dysfunction occurs premor-Whether this dysfunction occurs premorbidly (a potential cause of the illness) or bidly (a potential cause of the illness) or arises as a consequence of the disorder (a arises as a consequence of the disorder (a 'biological scar') should be addressed 'biological scar') should be addressed further by examination and longitudinal further by examination and longitudinal follow-up of a larger rigorously defined follow-up of a larger rigorously defined population at high risk of developing population at high risk of developing bipolar disorder. bipolar disorder.
Future studies Future studies
Our results suggest that HPA axis dysfunc-Our results suggest that HPA axis dysfunction may be involved in the disease process tion may be involved in the disease process underlying bipolar disorder. Further stu-underlying bipolar disorder. Further studies should examine the temporal evolu-dies should examine the temporal evolution of HPA axis function and bipolar tion of HPA axis function and bipolar disorder. disorder. The degree of abnormality is equal in remitted and non-remitted patients.
& & Abnormal function of the HPA axis may confer vulnerability to bipolar disorder. Abnormal function of the HPA axis may confer vulnerability to bipolar disorder.
LIMITATIONS LIMITATIONS
& & This study is cross-sectional. This study is cross-sectional.
& & We did not study patients in the manic phase.
We did not study patients in the manic phase.
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